Edwards Lifesciences Corporation
EWNYSEHealthcare● Active
$85.96
$-1.49(-1.70%)
Market Cap$49.5B
P/E Ratio—
52W High$89.445
52W Low$72.3
Edwards Lifesciences Corporation (EW) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · EW · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $6.07B | $5.44B | $5.01B | $5.38B | $5.23B |
| Cost of Revenue | $1.33B | $1.12B | $1.04B | $1.17B | $1.23B |
| Gross Profit | $4.74B | $4.32B | $3.97B | $4.22B | $4.01B |
| Gross Margin %(computed) | 78.13% | 79.46% | 79.30% | 78.31% | 76.57% |
| Operating Expenses | |||||
| R&D Expenses | $1.08B | $1.05B | $0.96B | $0.95B | $0.90B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $3.10B | $2.94B | $2.55B | $2.51B | $2.40B |
| Operating Income | $1.64B | $1.38B | $1.43B | $1.70B | $1.61B |
| Operating Margin %(computed) | 26.97% | 25.35% | 28.49% | 31.63% | 30.78% |
| Interest Income | $0.15B | $0.12B | $0.07B | $0.04B | $0.02B |
| Interest Expense | $0.00B | $0.02B | $0.02B | $0.03B | $0.02B |
| Income Before Tax | $1.27B | $1.55B | $1.37B | $1.77B | $1.70B |
| Income Tax Expense | $0.22B | $0.15B | $0.15B | $0.25B | $0.20B |
| Net Income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| Net Margin %(computed) | 17.69% | 76.75% | 27.99% | 28.28% | 28.73% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.84 | $6.98 | $2.31 | $2.46 | $2.41 |
| Wtd Avg Shares | 0.58B | 0.60B | 0.61B | 0.62B | 0.62B |
| EBITDA | $1.43B | $1.72B | $1.53B | $1.96B | $1.89B |
| EBITDA Margin %(computed) | 23.56% | 31.68% | 30.64% | 36.42% | 36.12% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Edwards Lifesciences Corporation data
About Edwards Lifesciences Corporation (EW) Income Statement
Edwards Lifesciences Corporation (EW) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, EW reported revenue of $6.07B, gross profit of $4.74B (gross margin 78.13%), and net income of $1.07B — a net profit margin of 17.69%.
Frequently asked questions
EW · 4 questionsEdwards Lifesciences Corporation (EW) reported revenue of $6.07B for 2025, up 11.5% year-over-year.
EW revenueEW salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08